Penumbra Inc. (NYSE:PEN) shares surged 6.29% in after-hours trading on Tuesday, following the release of its impressive fourth-quarter results and optimistic 2025 guidance. The medical device maker reported adjusted earnings of $0.97 per share, comfortably beating analysts' expectations of $0.90 per share. Revenue for the quarter came in at $315.52 million, outperforming the consensus estimate of $311.55 million.
The company's solid performance was driven by robust demand for its products, with revenue increasing by 10.83% compared to the same period last year. Penumbra's management team expressed confidence in the company's growth prospects, guiding for full-year 2025 revenue between $1.34 billion and $1.36 billion, which aligns with analysts' expectations.
Investors reacted positively to Penumbra's strong results and upbeat guidance, sending the stock soaring in after-hours trading. The medical device industry continues to benefit from increasing healthcare spending and technological advancements, positioning Penumbra well for continued growth in the coming year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.